Lupin celebrates grand opening of expanded New Jersey facilities

Lupin celebrates grand opening of expanded New Jersey facilities

SOMERSET, N.J. — Corporate leadership of Lupin Limited gathered along with state and local leaders on Tuesday to celebrate the grand opening of the company’s 100,000-sq.-ft. expansion of its manufacturing facilities here.  According to Lupin, the new facility will focus on making affordable medicines for treatment in various therapeutic areas.

“We are very pleased to officially open our new facility at Somerset,” said Vinita Gupta, CEO of Lupin Limited. “This expansion enables us to serve the growing need for affordable medicines for U.S. patients, providers, government and other stakeholders. In the last three years, we have made strategic investments in the U.S. in R&D and manufacturing to establish a deeper footprint in the country, and access technology capabilities for niche technology platforms.”

Among the politicians on hand to celebrate the grand opening was U.S. Rep. Bonnie Watson Coleman (D-N.J.).

“There’s no better place in the world to make significant investments in the biopharmaceutical industry, and in just over a year, Lupin has doubled down on its economic investment in the Somerset community and the global pharmaceutical landscape,” said Watson Coleman. “By expanding their facilities, this organization is not only putting more residents of New Jersey’s 12th congressional district to work, but also, focusing on making affordable medicine for patients worldwide.”

In March 2016, Lupin acquired the Somerset facility for $880 million. Since acquisition, more than 80 jobs have been created to support the site bringing the total number of employees in Somerset up to 380. Fifty more jobs are expected to be added over the next 12 to 18 months.

“The opening of this facility in Somerset enhances our scale in the U.S. generic market, and is a complement to Lupin’s Coral Springs, Florida, inhalation R&D center,” stated Lupin president Kurt Nielsen. “We have set ambitious targets for ourselves in the U.S. market. This 10-fold expansion of our manufacturing site will enable us to meet and exceed our targets. We are confident that we will continue to grow, and look forward to creating additional opportunities which benefit our community.”

 May 9, 2017 | By Brian Berk

Source: http://www.drugstorenews.com/

May 9, 2017 / Pharma News